Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
2 clinical trials · Condition
◉ Watch Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
| Record | Firm | Date |
|---|---|---|
| Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours (NCT02260661) | AstraZeneca | 2014-11-01 |
Track Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation automatically
Every clearance here is in the API, with alerts when new ones post.